Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Topics

Page Path

HOME
TOPICS
Topics

Erratum

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(2):669-670. Published online February 27, 2025

DOI: https://doi.org/10.3350/cmh.2024.0333e
Corrects: Clin Mol Hepatol 2024;30(4):807

View: 798 Download: 42

Snapshot

Modulation of lymphatic vessels in management of liver disease and complications

Aarti Sharma, Pinky Juneja, Shiv K Sarin, Savneet Kaur

Clin Mol Hepatol. 2025;31(2):665-668. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0793

View: 891 Download: 61 Crossref: 1

Editorial

Screening of patients at high risk of de novo recurrence in HCC: Editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”

Ping Huang, Shiqiao Luo, Rui Liao

Clin Mol Hepatol. 2025;31(2):662-664. Published online February 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0106

View: 531 Download: 27

Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):658-661. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0155

View: 565 Download: 37 Crossref: 2

Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang

Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0133

View: 995 Download: 57 Crossref: 1

Tetraspan(in)-mediated immune regulation in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8⁺ T cell cytotoxic function in hepatocellular carcinoma”

Seo Hee Jin, Dong Joo Kim, Jung Weon Lee

Clin Mol Hepatol. 2025;31(2):650-653. Published online February 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0109

View: 641 Download: 66

TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Chen Rui Yuan, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(2):646-649. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0102

View: 621 Download: 37

Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Valerie Chew

Clin Mol Hepatol. 2025;31(2):642-645. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0031

View: 738 Download: 45 Crossref: 1

Is AMA M2 a useful serologic test for screening high-risk patients for PBC?: Editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”

Nae-Yun Heo

Clin Mol Hepatol. 2025;31(2):640-641. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0117

View: 535 Download: 27 Crossref: 1

Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”

Naoshi Nishida

Clin Mol Hepatol. 2025;31(2):635-639. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0071

View: 578 Download: 25 Crossref: 1

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Nahee Hwang, Sungsoon Fang

Clin Mol Hepatol. 2025;31(2):631-634. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0066

View: 826 Download: 41 Crossref: 2

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):628-630. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0036

View: 976 Download: 38 Crossref: 2

Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Jeayeon Park, Su Jong Yu

Clin Mol Hepatol. 2025;31(2):625-627. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0019

View: 694 Download: 16

Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng

Clin Mol Hepatol. 2025;31(2):620-624. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1131

View: 1385 Download: 58 Crossref: 2

Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Georg Semmler, Lorenz Balcar, Mattias Mandorfer

Clin Mol Hepatol. 2025;31(2):615-619. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1180

View: 700 Download: 43 Crossref: 2

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 806 Download: 39 Crossref: 2

Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Chih-Wen Wang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(2):606-609. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.1078

View: 821 Download: 27 Crossref: 1

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Robert J. Wong

Clin Mol Hepatol. 2025;31(2):603-605. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0929

View: 663 Download: 21 Crossref: 1

Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis: Editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Hyuk soo Eun

Clin Mol Hepatol. 2025;31(2):599-602. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1133

View: 757 Download: 41 Crossref: 2

Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Eun Sun Jang

Clin Mol Hepatol. 2025;31(2):596-598. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0992

View: 725 Download: 18 Crossref: 1

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”

Myeung Gi Choi, Na Young Lee, Ja Hyun Koo

Clin Mol Hepatol. 2025;31(2):592-595. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0971

View: 1111 Download: 67

Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Jongman Kim

Clin Mol Hepatol. 2025;31(2):589-591. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0076

View: 611 Download: 34 Crossref: 1

A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Atsumasa Komori

Clin Mol Hepatol. 2025;31(2):584-588. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0945

View: 847 Download: 40 Crossref: 1

Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Nilanga Nishad

Clin Mol Hepatol. 2025;31(2):581-583. Published online November 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0942

View: 737 Download: 34 Crossref: 1

From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”

Akhil Deshmukh, Rakhi Maiwall

Clin Mol Hepatol. 2025;31(2):577-580. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0661

View: 2055 Download: 30 Crossref: 1

Original Article

Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma

Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):563-576. Published online January 13, 2025

DOI: https://doi.org/10.3350/cmh.2024.0899

View: 1092 Download: 78

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1044 Download: 97 Crossref: 1

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0835

View: 3376 Download: 275 Crossref: 5

Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity

Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang

Clin Mol Hepatol. 2025;31(2):509-524. Published online January 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.0545

View: 1372 Download: 116

Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma

Weifeng Zeng, Furong Liu, Yachong Liu, Ze Zhang, Haofan Hu, Shangwu Ning, Hongwei Zhang, Xiaoping Chen, Zhibin Liao, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):489-508. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0934

View: 2215 Download: 292 Crossref: 6

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Viewed By 9995	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7136	MAFLD: How is it different from NAFLD?
Viewed By 5121	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4654	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4608	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 304	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 205	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 103	Non-alcoholic fatty liver disease: Definition and subtypes